Opinion|Videos|February 17, 2025
Considerations for Switching Systemic Agents in Atopic Dermatitis
Panelists discuss the prevalence of treatment-refractory moderate to severe atopic dermatitis, noting factors such as intolerance or inability to use high-potency topical agents as common reasons for treatment failure, and emphasize the importance of considering alternative agents or switching treatments when necessary, particularly in pediatric patients, with biologics and Janus kinase (JAK) inhibitors being key options as evidenced by studies such as Blauvelt 2023, Keow & Abu-Hilal 2024 , and JADE EXTEND.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How prevalent is treatment-refractory moderate to severe atopic dermatitis?
- What are other reasons for treatment failure (eg, intolerance, inability to use high-potency topical agents)?
- When do you consider adding or switching agents?
- What other treatment options exist for pediatric atopic dermatitis?
- How do you determine which treatment to switch to?
- Biologic to JAK inhibitor: Blauvelt 2023, Keow & Abu-Hilal 2024, JADE EXTEND, Shi 2022
Advertisement
Related to this article
Researchers discuss how testosterone changes during early puberty may influence depression and anxiety symptoms in girls and implications for pediatricians.
A Mott Poll of 2,027 parents found 81% say having a baby costs too much; 73% strongly back state paid leave around birth.
In phase 3 SHINE-2, 50% of mirikizumab induction responders aged 6 to 17 with moderate to severe UC were in clinical remission at week 52.
Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
Learn when your baby is ready for solids, choose safe purees or finger foods, prevent choking, prioritize iron, and introduce allergens confidently.
Christina Boull, MD, shares recommendations for infant skin care, including choosing gentle cleansers, avoiding irritants, and supporting the skin barrier.
Completing the DTaP primary series was 96.2% effective against pertussis in Alaska children aged 6 months to 6 years during a record 2024 outbreak.
Keisha L. Gibson, MD, MPH, discusses the FDA approval of Gazyva for childhood-onset INS and its implications for relapse prevention and pediatric care.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Hand, foot, and mouth disease: Red flags pediatricians should know
2
Infant skin care: Choosing products that protect the skin barrier
3
Testosterone changes linked to emotional distress in pubertal girls
4
Mirikizumab meets 1-year remission end point in pediatric UC
5